Sight Sciences (SGHT) Stock Price, Financials & Analysis

Key Stats

Market Cap589.85 Mn

P/E-20.76

FCF (Yr)-29.92 Mn

ROA (Yr)-29.77

EV to EBIT-9.80

Net Income (Yr)-38.43 Mn

Enterprise Value255.77 Mn

Add ratio to table…

About

Sight Sciences Inc develops interventional medical devices for the treatment of glaucoma and dry eye disease. The company focuses on creating technologies that address the underlying physiological causes of these eye conditions. Its products enable eye care professionals to perform minimally invasive procedures that aim to preserve and restore natural eye function. Sight Sciences Inc operates primarily in the United States with additional presence in Europe. Sight Sciences…

Sight Sciences Inc generates revenue by selling its interventional devices and related accessories to health care providers. The company's main products are the OMNI Surgical System and the SION Surgical Instrument for glaucoma treatment and the TearCare system for dry eye treatment. Revenue is derived from direct sales in the United States and through distributors in select European markets. Customers include ambulatory surgery centers hospital outpatient departments and eye care practices.

The company operates through the following segments: Interventional Glaucoma and Interventional Dry Eye.

The Interventional Glaucoma segment includes the OMNI Surgical System and the SION Surgical Instrument which are used to perform minimally invasive glaucoma surgeries that reduce intraocular pressure by targeting the drainage pathways of the eye.
The Interventional Dry Eye segment consists of the TearCare system which delivers controlled thermal energy to melt meibomian gland obstructions and improve eyelid function in patients with evaporative dry eye disease.

Sight Sciences Inc competes in the medical device market for glaucoma and dry eye disease treatments. Its main competitors in the minimally invasive glaucoma surgery space include Glaukos Alcon AbbVie Iantrek New World Medical and Nova Eye Medical Limited. In the dry eye disease arena the company faces competition from Johnson & Johnson Alcon Abbvie and Novartis. Sight Sciences Inc differentiates itself by focusing on devices that treat the underlying physiological causes of disease and by generating strong clinical evidence to support product adoption.

The company sells its glaucoma products to ambulatory surgery centers and hospital outpatient departments where ophthalmic surgeons perform procedures. Its dry eye system is sold to optometry and ophthalmology practices that provide eye care services. Sight Sciences Inc also works with distributors in Europe to reach additional clinics and hospitals.

How Sight Sciences ranks

Ranked against the 247 companies in Medical Devices and Diagnostics58 metrics · as of Nov 6, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −18.9xMedian 26.9x 56^th
P/FCFNegative free cash flow −32.1xMedian 26.4x 50^th
P/Operating cash flowNegative operating cash flow −32.1xMedian 21.3x 48^th
P/S 6.14xMedian 2.88x 28^th
P/B 11.0xMedian 2.30x 7^th
P/Tangible book 11.0xMedian 2.97x 11^th
EV/EBITDANegative EBITDA −20.5xMedian 17.5x 43^rd
EV/EBITNegative EBIT −19.4xMedian 26.6x 46^th
EV/Revenue 5.73xMedian 3.14x 28^th
EV/FCFNegative free cash flow −29.9xMedian 29.7x 43^rd
EV/Operating cash flowNegative operating cash flow −29.9xMedian 21.1x 41^st
PEG (3Y EPS CAGR)Negative earnings −0.73Median 0.89 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) 16.2%Median 9.1% 64^th
Revenue CAGR (3Y) 2.2%Median 7.7% 33^rd
Gross profit growth (1Y) 18.5%Median 13.2% 61^st
Gross profit CAGR (3Y) 3.4%Median 9.4% 32^nd
Operating income growth (1Y) 42.5%Median 10.6% 79^th
Operating income CAGR (3Y) 25.5%Median 8.2% 72^nd
Net income growth (1Y) 38.4%Median 11.3% 73^rd
Net income CAGR (3Y) 22.8%Median 10.1% 69^th
EPS growth (1Y) 41.4%Median 28.4% 61^st
EPS CAGR (3Y) 25.9%Median 19.9% 56^th
Operating cash flow growth (1Y) 46.0%Median 5.0% 80^th
Operating cash flow CAGR (3Y) 33.0%Median 11.0% 74^th
Free cash flow growth (1Y) 46.9%Median 6.3% 77^th
Free cash flow CAGR (3Y) 33.2%Median 13.4% 74^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 87.7%Median 58.2% 98^th
EBITDA margin −28.0%Median −6.4% 40^th
Operating margin −29.5%Median −10.3% 43^rd
Pretax margin −32.1%Median −13.0% 41^st
Net margin −32.1%Median −12.2% 41^st
FCF margin −19.1%Median −3.4% 40^th
Operating cash flow margin −19.1%Median −1.5% 39^th
Return on equity −55.7%Median −21.8% 37^th
Return on assets −27.1%Median −17.1% 42^nd
Return on invested capital −28.4%Median 0.0% 26^th
Return on capital employed −30.8%Median −17.2% 39^th
Asset turnover 0.84xMedian 0.57x 72^nd
Cash conversion (OCF / net income)Net income is not positive 0.60xMedian 1.43x Not meaningful —
Stock comp / revenue 12.8%Median 5.7% 31^st

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 39.1%Median 28.7% 28^th
Debt / equity 0.84xMedian 0.46x 22^nd
Net debt / EBITDAEBITDA is not positive 1.47xMedian 2.45x Not meaningful —
Debt / FCFFree cash flow is not positive −2.43xMedian 4.03x Not meaningful —
Liabilities / assets 53.2%Median 45.7% 40^th
Equity / assets 46.8%Median 54.3% 40^th
Interest coverage −5.06xMedian −1.48x 41^st
Current ratio 5.04xMedian 2.90x 77^th
Quick ratio 4.51xMedian 1.87x 81^st
Cash ratio 3.84xMedian 1.16x 81^st
Altman Z-score 1.33Median 1.28 51^st

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TMO	Thermo Fisher Scientific Inc.	265.71 Bn	37.57	5.61	41.37 Bn
2	ABT	Abbott Laboratories	189.37 Bn	40.28	3.93	31.16 Bn
3	DHR	Danaher Corp /De/	164.78 Bn	38.05	6.43	26.48 Bn
4	ISRG	Intuitive Surgical Inc	157.85 Bn	53.38	13.63	-
5	MDT	Medtronic plc	129.66 Bn	24.79	3.45	28.15 Bn
6	SYK	Stryker Corp	121.82 Bn	33.62	4.63	14.93 Bn
7	BSX	Boston Scientific Corp	63.42 Bn	18.11	3.01	11.95 Bn
8	SGHT	Sight Sciences, Inc.	0.59 Bn	-20.76	6.67	0.04 Bn

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

TMO

Thermo Fisher Scientific Inc.

265.71 Bn

37.57

5.61

41.37 Bn

ABT

Abbott Laboratories

189.37 Bn

40.28

3.93

31.16 Bn

DHR

Danaher Corp /De/

164.78 Bn

38.05

6.43

26.48 Bn

ISRG

Intuitive Surgical Inc

157.85 Bn

53.38

13.63

MDT

Medtronic plc

129.66 Bn

24.79

3.45

28.15 Bn

SYK

Stryker Corp

121.82 Bn

33.62

4.63

14.93 Bn

BSX

Boston Scientific Corp

63.42 Bn

18.11

3.01

11.95 Bn

SGHT

Sight Sciences, Inc.

0.59 Bn

-20.76

6.67

0.04 Bn

Sight Sciences SGHT

About

Segments Breakdown of Revenue (2025)

How Sight Sciences ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Sight Sciences SGHT

About

Segments Breakdown of Revenue (2025)

How Sight Sciences ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password